Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.
What if I purchased Capricor securities?
If you purchased Capricor securities and suffered losses on your investment, you may join our investigation now: Click Here to Join the Investigation.
Or for more information, contact James Baker at jimb@johnsonfistel.com or (619) 814-4471.
